Interprofessional Collaboration Between a Clinical Pharmacist and Specialty Physicians to Treat Hepatitis C in an Interdisciplinary Medical Practice Setting
- PMID: 36311306
- PMCID: PMC9608105
- DOI: 10.1177/87551225221125428
Interprofessional Collaboration Between a Clinical Pharmacist and Specialty Physicians to Treat Hepatitis C in an Interdisciplinary Medical Practice Setting
Abstract
Objective: Describes the activities of a clinical pharmacist in a gastroenterology (GI) clinic providing services to hepatitis C virus (HCV) patients, with a focus on practice management activities and tools. Practice Description: Located inside a GI specialty clinic in Fort Worth, Texas, the pharmacist provides comprehensive medication management under a collaborative practice agreement (CPA). Once referred by the GI physician, the pharmacist has face-to-face patient visits, develops the care plan, orders medications, and follows patients through sustained virologic response and the development of a hepatocellular carcinoma surveillance plan. Practice Innovation: The role of pharmacists in the management of HCV is important to understand. This article details a pharmacist-led clinic in an open GI medical practice. Evaluation: A retrospective chart review study was conducted to assess outcomes related to the integration of the clinical pharmacist. Methods: Completed by the study team, this study included manual chart reviews of patients with the ambulatory care pharmacist-driven HCV practice to pull data and information that were then tabulated using Qualtrics. Results: A total of 95 charts were surveyed, 78 records were created, and 49 patients were started on direct-acting antiviral (DAA) treatment by the pharmacist. Patients required multiple pharmacist communication actions. The minimum duration of the pharmacist service was 6 months and could extend more than 9 months depending on the time it took to get the patient started on medication. Pharmacist integration into the practice resulted in improved intake for the GI clinic, improved interprofessional interaction, and increased utilization of newer treatment modalities for HCV which feature cure rates up to 99% with limited side effects. Conclusion: Clinical pharmacists are well positioned to help navigate patients through the complexities of the medication use system, medication access, drug interactions and adverse effects, promote medication adherence, and allow patients to start and complete therapy.
Keywords: antivirals; clinical pharmacist practice site; direct-acting antivirals; hepatitis C; pharmacist-led service; pharmacists.
© The Author(s) 2022.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures
Similar articles
-
Developing a multidisciplinary HCV direct-acting antivirals utilization management and assessment program.J Am Pharm Assoc (2003). 2021 Mar-Apr;61(2):e159-e170. doi: 10.1016/j.japh.2020.11.008. Epub 2020 Dec 9. J Am Pharm Assoc (2003). 2021. PMID: 33309191
-
Pharmacist-led drug therapy management for hepatitis C at a federally qualified health care center.J Am Pharm Assoc (2003). 2022 Sep-Oct;62(5):1596-1605. doi: 10.1016/j.japh.2022.04.014. Epub 2022 Apr 26. J Am Pharm Assoc (2003). 2022. PMID: 35595639
-
Assessing the proportion of patients with hepatitis C treated before and after initiation of an ambulatory pharmacist-led hepatitis C program: A retrospective analysis.J Am Pharm Assoc (2003). 2023 Jan-Feb;63(1):440-446. doi: 10.1016/j.japh.2022.09.006. Epub 2022 Sep 16. J Am Pharm Assoc (2003). 2023. PMID: 36272941
-
AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.Gastroenterology. 2019 Jun;156(8):2149-2157. doi: 10.1053/j.gastro.2019.02.046. Epub 2019 Mar 13. Gastroenterology. 2019. PMID: 30878469 Free PMC article. Review.
-
Effects of pharmacist prescribing on patient outcomes in the hospital setting: a systematic review.JBI Database System Rev Implement Rep. 2018 Sep;16(9):1823-1873. doi: 10.11124/JBISRIR-2017-003697. JBI Database System Rev Implement Rep. 2018. PMID: 30204671
Cited by
-
Use of Pharmacists and Collaborative Practice Agreements to Treat Hepatitis C: A Survey of Primary Care Clinicians in Washington State.J Prim Care Community Health. 2025 Jan-Dec;16:21501319251359547. doi: 10.1177/21501319251359547. Epub 2025 Jul 30. J Prim Care Community Health. 2025. PMID: 40737114 Free PMC article.
-
Micro-elimination initiative for hepatitis C screening: insight into gender gaps and undiagnosed individuals.Sci Rep. 2025 Mar 18;15(1):9289. doi: 10.1038/s41598-025-91696-4. Sci Rep. 2025. PMID: 40102477 Free PMC article.
References
-
- Centers for Disease Control and Prevention. Hepatitis C fact sheet. Date unknown. Accessed May 25, 2022. https://www.cdc.gov/hepatitis/hcv/index.htm.
-
- Centers for Disease Control and Prevention. Hepatitis C questions and answers for health professionals. Date unknown. Accessed May 25, 2022. https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm.
-
- Daniel KE, Saeian K, Rizvi S. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment. J Viral Hepat. 2020;27(2):195-204. - PubMed
LinkOut - more resources
Full Text Sources